HER2 status in gastric adenocarcinoma of Chinese: a multicenter study of 40 842 patients
10.3760/cma.j.issn.0529-5807.2018.11.002
- VernacularTitle: 中国人40 842例胃腺癌HER2多中心检测结果分析
- Author:
Dan HUANG
1
;
Zengshan LI
;
Xiangshan FAN
;
Hongmei WU
;
Jianping LIU
;
Wenyong SUN
;
Shanshan LI
;
Yinyong HOU
;
Xiu NIE
;
Jun LI
;
Rong QIN
;
Lingchuan GUO
;
Jinghong XU
;
Huizhong ZHANG
;
Miaomiao SUN
;
Qiaonan GUO
;
Yinghong YANG
;
Yanhui LIU
;
Yu QIN
;
Lijuan ZHANG
;
Jinghe LI
;
Zhihong ZHANG
;
Peng GAO
;
Yujun LI
;
Weiqi SHENG
Author Information
1. Department of Pathology, Cancer Hospital, Fudan University, Shanghai 200032, China
- Collective Name:Cooperative Gastric Cancer Study Group of China Anti-Cancer Association Tumor Pathology Committee
- Publication Type:Journal Article
- Keywords:
Stomach neoplasms;
Multicenter study;
Genes, erbB-2;
Immunohistochemistry;
In situ hybridization
- From:
Chinese Journal of Pathology
2018;47(11):822-826
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigation HER2 status in gastric adenocarcinoma of Chinese and contributing factors to the HER2 expression.
Methods:HER2 status of 40 842 gastric adenocarcinomas and clinical data were retrospectively collected from 23 hospitals dated from 2013 to 2016. The association between HER2 positivity and clinicopathologic features was analyzed.
Results:Of the 40 842 patients the median age was 62 years, the male female ratio was 2.6∶1.0. The rate of HER2 positivity was 8.8% (3 577/40 842). HER2 expression was related to the tissue type, tumor location, Lauren classification and tumor differentiation (P values: 0.009, 0.001, <0.01 and <0.01, respectively). Different HER2 expression status was observed between primary and recurrent tumors in 7.6% (48/635) cases. The rates of HER2 positivity ranged from 2% to 10% among different institutions. The rates of HER2 FISH amplification were dramatically different among the 23 hospitals (0-100%) with an average rate of 10% (810/8 156) in patients with HER2 IHC 2+ .
Conclusions:HER2 expression is associated with clinicopathologic characteristics. HER2 re-assessment of tumor tissue and use of in situ hybridization techniques increase HER2 positivity. The current retrospective study should reflect the HER2 status in gastric adenocarcinoma of Chinese patients.
